NLRP3 and hepatocellular carcinoma: Indeed, the pretreatment with MCC950 (NLRP3 blocker), wortmannin (PI3k blocker), and dorsomorphine (AMPK blocker) was able to counteract the reduction of cell viability and mitochondrial membrane potential (Figure 10A,B, Figure 11A,B and Figure 12A,B) and the increased ROS release by HUVEC (Figure 10C, Figure 11C and Figure 12C), in particular in HCV subjects with stages of disease from F1 to F4 without HCC.